Company news
Intellia Therapeutics, Inc. news in 2020
Intellia Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency
December 11, 2020
Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting
December 4, 2020
Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 3, 2020
Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
November 10, 2020
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
November 8, 2020
Intellia Therapeutics Announces Third Quarter 2020 Financial Results
November 4, 2020
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates
October 28, 2020
Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)
October 18, 2020
Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology
October 6, 2020
Intellia Therapeutics Names John F. Crowley to Board of Directors
October 4, 2020
Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment
September 28, 2020
Intellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines Conference
September 27, 2020
Intellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare Conference
September 1, 2020
Intellia Therapeutics Announces Second Quarter 2020 Financial Results
August 5, 2020
Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 2, 2020
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates
July 29, 2020
GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms
July 19, 2020
Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 4, 2020
Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
May 11, 2020
Intellia Therapeutics Announces First Quarter 2020 Financial Results
May 6, 2020
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates
April 29, 2020
Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
April 29, 2020
Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
April 27, 2020
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics
March 30, 2020
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results
February 26, 2020
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update
February 19, 2020
Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference
February 9, 2020
Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones
January 8, 2020
Decks in 2020
- Technical Presentation (December 2020)
Technical · 11 slides · Dec 5, 2020